The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

NCT06439693 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Female
Breast Cancer
Breast Cancer Metastatic
Estrogen Receptor-positive Breast Cancer
HER2-positive Breast Cancer
Stage IV Breast Cancer

Interventions

DRUG: Nab-Paclitaxel
DRUG: Paclitaxel
DRUG: Docetaxel
DRUG: Phesgo
DRUG: T-DM1
DRUG: Pertuzumab
DRUG: Trastuzumab Deruxtecan
DRUG: Trastuzumab Subcutaneous Subcutaneous
DRUG: Tucatinib
DRUG: Trastuzumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]